Nathan R Miselis
Overview
Explore the profile of Nathan R Miselis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weaver A, Iams W, Park J, Mita M, Holtick U, Gordon M, et al.
Mol Carcinog
. 2024 May;
63(8):1421-1428.
PMID: 38695604
Cancer vaccines strive to induce robust, antigen-targeted, T-cell-mediated immune responses but have struggled to produce meaningful regression in solid tumors. An autologous cell vaccine, SQZ-PBMC-HPV, was developed by SQZ Biotechnologies...
2.
Jimeno A, Baranda J, Iams W, Park J, Mita M, Gordon M, et al.
Invest New Drugs
. 2023 Mar;
41(2):284-295.
PMID: 36867316
We conducted a dose escalation Phase 1 study of autologous PBMCs loaded by microfluidic squeezing (Cell Squeeze technology) with HPV16 E6 and E7 antigens (SQZ-PBMC-HPV), in HLA-A*02+ patients with advanced/metastatic...
3.
Moschos S, Sullivan R, Hwu W, Ramanathan R, Adjei A, Fong P, et al.
JCI Insight
. 2018 Feb;
3(4).
PMID: 29467321
Background: Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations of MAPK inhibitor blockade....
4.
Guertin A, Martin M, Roberts B, Hurd M, Qu X, Miselis N, et al.
Cancer Cell Int
. 2012 Nov;
12(1):45.
PMID: 23148684
Unlabelled: Background: Inhibition of kinases involved in the DNA damage response sensitizes cells to genotoxic agents by abrogating checkpoint-induced cell cycle arrest. CHK1 and WEE1 act in a pathway upstream...
5.
Miselis N, Lau B, Wu Z, Kane A
Cancer Microenviron
. 2011 Apr;
4(1):39-50.
PMID: 21505561
Unlabelled: Diffuse malignant mesothelioma is an aggressive tumor which displays a median survival of 11.2 months and a 5-year survival of less than 5% emphasizing the need for more effective...
6.
Sanchez V, Pietruska J, Miselis N, Hurt R, Kane A
Wiley Interdiscip Rev Nanomed Nanobiotechnol
. 2010 Jan;
1(5):511-29.
PMID: 20049814
Human diseases associated with exposure to asbestos fibers include pleural fibrosis and plaques, pulmonary fibrosis (asbestosis), lung cancer, and diffuse malignant mesothelioma. The critical determinants of fiber bioactivity and toxicity...
7.
Miselis N, Wu Z, van Rooijen N, Kane A
Mol Cancer Ther
. 2008 Apr;
7(4):788-99.
PMID: 18375821
Tumors are a mixture of neoplastic and host stromal cells, which establish a microenvironment that contributes to tumor progression. In this study, the contribution of tumor-associated macrophages (TAMs) to tumor...